CA2576643A1 - Screening assays for inhibitors of a staphylococcus aureus siderophore - Google Patents

Screening assays for inhibitors of a staphylococcus aureus siderophore Download PDF

Info

Publication number
CA2576643A1
CA2576643A1 CA002576643A CA2576643A CA2576643A1 CA 2576643 A1 CA2576643 A1 CA 2576643A1 CA 002576643 A CA002576643 A CA 002576643A CA 2576643 A CA2576643 A CA 2576643A CA 2576643 A1 CA2576643 A1 CA 2576643A1
Authority
CA
Canada
Prior art keywords
seq
sbn
polypeptide
aureus
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002576643A
Other languages
English (en)
French (fr)
Inventor
Suzanne Dale
David E. Heinrichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Ontario
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2576643A1 publication Critical patent/CA2576643A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002576643A 2004-09-08 2005-09-08 Screening assays for inhibitors of a staphylococcus aureus siderophore Abandoned CA2576643A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60789604P 2004-09-08 2004-09-08
US60/607,896 2004-09-08
PCT/IB2005/004081 WO2006043182A2 (en) 2004-09-08 2005-09-08 Screening assays for inhibitors of a staphylococcus aureus siderophore

Publications (1)

Publication Number Publication Date
CA2576643A1 true CA2576643A1 (en) 2006-04-27

Family

ID=36203330

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002576643A Abandoned CA2576643A1 (en) 2004-09-08 2005-09-08 Screening assays for inhibitors of a staphylococcus aureus siderophore

Country Status (7)

Country Link
US (1) US20110206685A1 (enExample)
EP (1) EP1786907A4 (enExample)
JP (1) JP2008512108A (enExample)
KR (1) KR20070083638A (enExample)
AU (1) AU2005297171A1 (enExample)
CA (1) CA2576643A1 (enExample)
WO (1) WO2006043182A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637657B2 (en) 2008-08-19 2014-01-28 David E. Heinrichs Siderophore-mediated iron uptake in bacterial infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000868A1 (en) * 1992-06-26 1994-01-06 Materials Research Corporation Transport system for wafer processing line
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002353764A1 (en) * 2001-06-17 2003-03-18 D-Squared Biotechnologies, Inc. Staphylococci surface-exposed immunogenic polypeptides
US6605459B2 (en) * 2001-07-13 2003-08-12 Paradigm Genetics, Inc. Methods for measuring cysteine and determining cysteine synthase activity
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms

Also Published As

Publication number Publication date
WO2006043182A2 (en) 2006-04-27
WO2006043182A3 (en) 2006-09-21
EP1786907A2 (en) 2007-05-23
KR20070083638A (ko) 2007-08-24
AU2005297171A1 (en) 2006-04-27
JP2008512108A (ja) 2008-04-24
EP1786907A4 (en) 2009-01-21
US20110206685A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
WO2008152447A2 (en) Staphylococcus aureus specific anti-infectives
Terao et al. Fba, a novel fibronectin‐binding protein from Streptococcus pyogenes, promotes bacterial entry into epithelial cells, and the fba gene is positively transcribed under the Mga regulator
Dieudonné-Vatran et al. Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion
Stapleton et al. Mycobacterium tuberculosis cAMP receptor protein (Rv3676) differs from the Escherichia coli paradigm in its cAMP binding and DNA binding properties and transcription activation properties
EP1812066A2 (en) Staphylococcus aureus isd protein-based anti-infectives
Fritzer et al. Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine
US20050220788A1 (en) Use of molecules which interact with the haptoglobin receptor ligand binding
US20080050361A1 (en) Staphylococcus aureas specific anti-infectives
AU2005276144B2 (en) Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, FN Staphylococcus aureus
US20110206685A1 (en) Screening assays for inhibitors of a staphylococcus aureus siderophore
Kimoto et al. Genetic and biochemical properties of streptococcal NAD-glycohydrolase inhibitor
US8729013B2 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
McNitt et al. Streptococcal collagen-like protein 1 binds wound fibronectin: Implications in pathogen targeting
US20100129349A1 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
US20070292873A1 (en) Bacterial iron acquisition targets
US7749517B2 (en) Anthrax antitoxins
CA2506538C (en) Bacterial superantigen vaccines
Le Biochemical Analysis Of Modulation Of Sex Pheromone Production By Prgy, A Structural Homolog Of A Metalloprotease (Tiki) That Modulates Wnt Signaling In Eukaryotes
JP2002525048A (ja) Ｒｎａｓｅｐポリペプチド
WO2006137838A2 (en) Methods and compositions for diagnosing and preventing a group b streptococcal infection
Hoff An examination of the role of SpyA, an ADP-ribosyltransferase, in Streptococcus pyogenes pathogenesis
Swiatecka-Urban et al. The Pseudomonas aeruginosa secreted protein, PA2934, decreases 3 apical membrane expression of the cystic fibrosis transmembrane 4 conductance regulator 5
Ronholm et al. Monoclonal Antibodies Recognizing the Surface Autolysin IspC of Listeria

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150528